Polycystin-1 Downregulation Induced Vascular Smooth Muscle Cells Phenotypic Alteration and Extracellular Matrix

Jing Zhang1, Fei Liu2, Yu-Bin He1,3

  • 1Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

Frontiers in Physiology
|October 19, 2020
PubMed

Insights

Polycystin-1 (PC-1) downregulation in thoracic aortic dissection (TAD) alters vascular smooth muscle cell (VSMC) phenotypes and extracellular matrix (ECM) remodeling via the mTOR/S6K/S6 pathway. Rapamycin may inhibit TAD progression.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Vascular Cell Biology

Background:

  • Polycystin-1 (PC-1), encoded by the polycystic kidney disease-1 (PKD-1) gene, plays a role in cellular functions.
  • Thoracic aortic dissection (TAD) involves significant changes in aortic vascular smooth muscle cells (VSMCs) and extracellular matrix (ECM).

Purpose of the Study:

  • To investigate the regulatory mechanisms of PC-1 on VSMC phenotypes and ECM function in TAD.
  • To elucidate the role of PC-1 in the pathogenesis of TAD.

Main Methods:

  • Analysis of aortic tissues and primary VSMCs from TAD patients and controls.
  • Immunohistochemistry, immunofluorescence, immunocytochemistry, Western blot, and RT-qPCR were employed.
  • Lentivirus-mediated downregulation or overexpression of PC-1 in VSMCs.

Main Results:

  • PC-1 and VSMC contractile markers were decreased, while synthetic markers, MMP-2, collagen I, and collagen III were increased in TAD.
  • PC-1 downregulation promoted VSMC synthetic phenotypes and ECM remodeling, activating the mTOR/S6K/S6 pathway.
  • PC-1 upregulation reversed these effects, and rapamycin inhibited the changes induced by PC-1 downregulation.

Conclusions:

  • PC-1 downregulation drives VSMC phenotypic alteration and ECM remodeling through mTOR/S6K/S6 pathway activation in TAD.
  • PC-1 downregulation is a potential mechanism in TAD development and progression.
  • Rapamycin shows potential as an inhibitor to attenuate TAD development and progression.
Abstract